1
|
Mbaga DS, Bikoï JN, Okobalemba EA, Essindi JO, Mikangue CAM, Membangbi AE, Ngoutane A, Elang AF, Touangnou-Chamda SA, Sake CS, Mondinde GI, Kenmoe S, Essama SHR. Seroprevalence of hepatitis C virus antigen in patients with chronic liver disease and hepatocellular carcinoma at 12 th week of treatment: a cross-sectional study. Pan Afr Med J 2022; 43:72. [PMID: 36590993 PMCID: PMC9789782 DOI: 10.11604/pamj.2022.43.72.35450] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Accepted: 09/24/2022] [Indexed: 11/07/2022] Open
Abstract
Introduction epidemiological data suggests that more than 50% of hepatitis C virus (HCV) patients fail treatment. The objective of the study was to highlight the seroprevalence of hepatitis C virus antigen (HCV Ag) at the 12th week of treatment. Methods during a cross-sectional study, participants with chronic liver disease and hepatocellular carcinoma (HCC) were recruited between December 2020 and March 2022 at the Yaoundé General Hospital (HGY) and the University Teaching Hospital of Yaounde (UTHY). Five millilitres of blood samples were taken from each consenting participant and then a qualitative search for HCV Ag by Enzyme-Linked Immuno Assay (ELISA) was performed. Analysis of the results was performed using SPSS Version 25.0 software. Results out of the 192 participants selected for the study, only 92 (47,9%) participants were at 12 weeks of treatment, including 69 (75%) participants positive for the hepatitis C virus antibody (HCV Ab) by RDT. Of these participants, 44 (47.8%) participants were positive for HCV Ag by ELISA, respectively 19/37 (51.3%), 14/19 (73.6%), 11/13 (84.6%) with chronic hepatitis (HC), Cirrhosis, and HCC (P<0.0001). Conclusion our results showed a high prevalence of HCV Ag in patients at their 12th week of treatment which predicts treatment failure and calls for public policy to develop new management strategies to prevent HCV treatment failure in our context.
Collapse
Affiliation(s)
| | - Jacky Njiki Bikoï
- Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon
| | | | | | | | | | - Aïcha Ngoutane
- Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon,,Institute of Medical Research and Medicinal Plant Study, Yaoundé, Cameroon
| | | | | | | | - George Ikomey Mondinde
- Faculty of Medicine and Biomedical Sciences, The University of Yaoundé I (Center for the Study and Control of Communicable Diseases (CSCCD), Yaoundé, Cameroon
| | - Sebastien Kenmoe
- Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon
| | - Sara Honorine Riwom Essama
- Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon,,Corresponding author: Sara Honorine Riwom Essama, Department of Microbiology, The University of Yaoundé I, Yaoundé, Cameroon.
| |
Collapse
|
2
|
Ngwa CH, Doungtsop BCK, Bihnwi R, Ngo NV, Yang NM. Burden of vaccine-preventable diseases, trends in vaccine coverage and current challenges in the implementation of the expanded program on immunization: A situation analysis of Cameroon. Hum Vaccin Immunother 2021; 18:1939620. [PMID: 34197271 PMCID: PMC8920166 DOI: 10.1080/21645515.2021.1939620] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The discovery and development of vaccines remain one of the major successes of global health with millions of lives saved every year through routine vaccination. Although vaccines provide a safe and cost-effective solution to vaccine-preventable diseases (VPDs), VPDs are still a serious public health problem in most parts of the world, especially in sub-Saharan Africa (SSA) and Asia. In this review, we discuss the burden of VPDs and vaccine coverage several decades after the introduction of the Expanded Program on Immunization (EPI) in Cameroon. We also discuss how different factors affect the implementation of the EPI, highlighting context-specific factors such as the ongoing civil conflict in Cameroon, and the presence of other infectious diseases like COVID-19.
Collapse
Affiliation(s)
- Che Henry Ngwa
- School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.,Centre for Languages and Literature, Lund University, Lund, Sweden
| | | | | | - Ngo Valery Ngo
- School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Niendum Mediatrice Yang
- School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| |
Collapse
|